J&J's Janssen Gets FDA Breakthrough Therapy Designation for RSV Vaccine in Older Adults
September 03 2019 - 10:44AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Tuesday said the U.S. Food and Drug Administration granted
breakthrough-therapy designation for its investigational vaccine
for the prevention of respiratory syncytial virus in adults at
least 60 years of age.
Janssen said there are no preventive vaccines or effective
antiviral treatments currently available for RSV, a
highly-contagious, potentially life-threatening respiratory
infection that affects more than 64 million people a year.
The FDA's breakthrough-therapy designation aims to expedite the
development and review of a drug for serious conditions when
preliminary clinical evidence shows the drug may show substantial
improvement over available therapies.
Janssen said older adults are among those at highest risk of
developing RSV. The company said its investigational vaccine is
currently in a phase 2b proof-of-concept study in adults who are at
least 65 years old.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 03, 2019 10:29 ET (14:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024